Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita (NYSE:DVA) unveiled its 2030 Community Care commitments after achieving most prior five-year ESG goals. New targets focus on patient outcomes, teammate opportunity, and community and environmental resilience.
Plans include expanded kidney education, more transplants, sustained high engagement, greater volunteerism, and continued 100% renewable energy use.
DaVita (NYSE: DVA) announced that CFO Joel Ackerman and Group VP of Investor Relations Nic Eliason will speak in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 5:20 PM ET. A live webcast is available via the BofA page with free registration.
As of March 31, 2026, DaVita served approximately 296,300 patients at 3,262 outpatient dialysis centers worldwide, including 2,666 US centers and 596 centers across 14 other countries.
DaVita (NYSE: DVA) reported Q1 2026 results for the quarter ended March 31, 2026. Consolidated revenue was $3.416 billion, operating income $482 million, diluted EPS from continuing operations $2.87, operating cash flow $321 million and free cash flow $140 million. The company repurchased 3.0 million shares for $403 million in Q1 and repurchased an additional 2.0 million shares for $302 million through May 5, 2026.
As of March 31, 2026, DaVita served ~296,300 patients at 3,262 centers and had ~62,600 patients in risk-based integrated kidney care representing ~$5.4 billion annualized medical spend.
Honeywell (NASDAQ: HON) announced the anticipated 11‑member Board of Directors for the planned standalone Honeywell Aerospace, led by Independent Chair Craig Arnold and including CEO Jim Currier. The spin‑off is expected to be completed on June 29, 2026, with an Investor Day scheduled for June 3, 2026.
The board combines aerospace, defense, finance, and capital‑markets experience intended to support electrification, autonomy, and safety initiatives as the company launches as a public pure‑play aerospace and defense firm.
DaVita (NYSE: DVA) will host its first quarter 2026 earnings conference call on Tuesday, May 5, 2026 at 5:00 p.m. Eastern Time. The company will release results after market close the same day and will webcast the call on its investor relations site.
Investors can join via webcast or by dialing the provided domestic and international numbers; a website replay will be available after the live event.
DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.
Key points: a 9% Total Quality Score improvement, >$200 million in cumulative shared savings, and management of $5+ billion in medical costs under management, tied to better treatment starts and reduced catheter use.
Alebund Pharmaceuticals (NYSE:DVA) granted R1 Therapeutics exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China and received a substantial non-dilutive equity stake in R1.
The deal includes up to low triple‑digit millions in milestone payments, tiered royalties in the low double‑digit percent range, and a planned global Phase 2b MRCT starting later this year.
DaVita (NYSE: DVA) will participate in TD Cowen's 46th Annual Health Care Conference with CFO Joel Ackerman and VP of Investor Relations Nic Eliason in a fireside chat on March 2, 2026 at 11:50 am EST. A live webcast is available via TD Cowen with free registration.
As of Dec 31, 2025, DaVita served ~295,000 patients across 3,242 outpatient dialysis centers globally.
DaVita (NYSE: DVA) reported consolidated revenues of $3.620B for Q4 2025 and $13.643B for full-year 2025, adjusted diluted EPS of $3.40 (Q4) and $10.78 (2025), operating cash flow of $541M (Q4) and free cash flow of $1,024M (2025).
The company refinanced Term Loan A-1, issued 6.75% senior notes due 2033, repurchased 12.7M shares in 2025, and provided 2026 guidance for adjusted operating income and adjusted EPS.
Elara Caring announced a strategic investment from Ares and DaVita (DVA) to expand clinically advanced, in‑home care for complex and high‑acuity patients. The partners will co‑develop a kidney‑specific home care model and support Elara’s scale-up while Elara remains an independent company led by CEO Ananth Mohan.
The transaction is subject to customary closing conditions and regulatory approvals, with closing expected later in 2026; financial terms were not disclosed.